Skip to main content
OpenTrials
Completed

NCT Number: NCT02889068

Targeted Next Generation Sequencing and Intellectual Disability

The purpose is to determine the benefit of next generation sequencing (NGS) targeted on genes involved in intellectual disability for etiologic diagnosis of intellectual disabilities. In other words, it concerns the number of patients whose etiologic diagnosis will be established with NGS and could not with common techniques. Actually, the molecular etiology of intellectual disability is crucial to calculate the risk of recurrence and allows the perinatal diagnosis to these families.

Secondary purposes are:

1. To determine the place of NGS in the strategy of etiologic diagnosis of intellectual disability, to determine the order of analyses performed for a patient with intellectual disability without clinical signs. 2. To evaluate the number of variants with unknown significance and thus non-usable for genetic counselling without supplementary analysis. 3. To determine the number of samples that can be at most pooled keeping a good efficacy of capture and results with suitable read depth 4. To determine the possibility of detecting copy number variations (CNVs) in genes of interest with NGS 5. To establish genotype/phenotype correlations for each gene for which a mutation has been identified 6. To optimize the software pipelining for a rapid analysis for diagnosis.

Completed

Looking for future studies?

Notify Me

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Moderate or severe intellectual disability
  • Availability of patient and parent DNA
  • No etiologic diagnosis with standard approaches: negative fragile X, normal pangenomic 180K and 1M array-CGH
  • Informed consent of person having parental authority

Exclusion criteria

  • Non availability of parent DNA
  • Patient lost to follow-up

Treatment and study plan

blood sample

Other

Primary outcomes

  1. Percentage of patients with certain etiologic diagnosis established with NGS

    Time frame: day 0

Secondary outcomes

  1. Percentage of patients with etiologic diagnosis established with NGS or with other techniques (array-CGH)

    Time frame: day 0

  2. Obtained read depth according to number of pooled samples

    Time frame: day 0

  3. Percentage of patients with variant with unknown significance, needing supplementary analyses to prove its involvement in intellectual disability

    Time frame: day 0

  4. CNVs detected with NGS or array-CGH (reference technique for CNV detection).

    Time frame: day 0

  5. Clinical phenotype for each gene for which a causal mutation is identified by NGS

    Time frame: day 0

  6. Time of analysis of NGS raw data

    Time frame: day 0

Sponsors and collaborators

Lead sponsor

Central Hospital, Nancy, France

Other

Registry information

Acronym: NGS-DI

Important dates

Study start
2015
Primary completion
2016
Study completion
2017
First posted
Sep 5, 2016
Registry last updated
Jul 28, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.